Results 31 to 40 of about 865,562 (415)
The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction.
Nanomedicine, 2016 Nanoparticle-based technologies offer exciting new approaches to disease diagnostics and therapeutics. To take advantage of unique properties of nanoscale materials and structures, the size, shape and/or surface chemistry of nanoparticles need to be ...
Nazanin Hoshyar +3 more
semanticscholar +1 more source
Journal of Pharmacy & Pharmaceutical Sciences, 2007 Purpose. GroB-T, a human CXC chemokine, has been studied for its potential to mobilize stem cells. Chemokines bind specifically to receptors on target immune cells but also to a homologous erythrocyte blood group antigen, the Duffy Antigen/Receptor for ...
Timothy W Hepburn +4 more
doaj +1 more source
mAbs, 2020 The decision to pursue a monoclonal antibody (mAb) as a therapeutic for disease intervention requires the assessment of many factors, such as target-biology, including the total target burden and its accessibility at the intended site of action, as well ...
Kip P. Conner +5 more
doaj +1 more source
Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
Clinical Pharmacokinetics, 2017 Dexmedetomidine is an α2-adrenoceptor agonist with sedative, anxiolytic, sympatholytic, and analgesic-sparing effects, and minimal depression of respiratory function.
Maud A. S. Weerink +5 more
semanticscholar +1 more source
The pharmacokinetics and the pharmacodynamics of cannabinoids.
British Journal of Clinical Pharmacology, 2018 There is increasing interest in the use of cannabinoids for disease and symptom management, but limited information available regarding their pharmacokinetics and pharmacodynamics to guide prescribers.
C. Lucas, P. Galettis, J. Schneider
semanticscholar +1 more source
Pharmacology Research & Perspectives, 2019 MGS0274 besylate is an ester‐based lipophilic prodrug of a metabotropic glutamate (mGlu) 2 and mGlu3 receptor agonist MGS0008 and being developed for the treatment of schizophrenia.
Kohnosuke Kinoshita +4 more
doaj +1 more source
Evaluation of dosing strategy for pembrolizumab for oncology indications
Journal for ImmunoTherapy of Cancer, 2017 Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability.
Tomoko Freshwater +6 more
doaj +1 more source
Clinical Pharmacokinetics and Pharmacodynamics of Propofol
Clinical Pharmacokinetics, 2018 Propofol is an intravenous hypnotic drug that is used for induction and maintenance of sedation and general anaesthesia. It exerts its effects through potentiation of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) at the GABAA receptor, and ...
M. Sahinovic, M. Struys, A. Absalom
semanticscholar +1 more source
Food intake attenuates the drug interaction between new quinolones and aluminum
Journal of Pharmaceutical Health Care and Sciences, 2018 Background Intestinal absorption of new quinolones is decreased by oral administration of polyvalent metal cations. Some clinical studies have demonstrated this drug - drug interaction is more prominent under fasted condition. However, the effect of food
Ayuko Imaoka +3 more
doaj +1 more source
Frontiers in Pharmacology, 2020 Cisplatin, carboplatin, and oxaliplatin are the common platinum-based anticancer drugs widely used in the chemotherapeutic treatment of solid tumors in clinic.
Zhiying Qin +8 more
doaj +1 more source